XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Investments (Tables)
 6 Months Ended
Jun. 30, 2021
Long Term Investment [Abstract]  
Schedule of ownership percentages of investee
   Ownership percentage    
   June 30,   December 31,   Accounting
Name of related party  2021   2020   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.70%   0.70%  Cost Method
BioHopeKing Corporation   5.90%   5.90%  Cost Method
BioFirst Corporation   15.99%   15.99%  Equity Method
Rgene Corporation   31.62%   31.62%  Equity Method

 
Schedule of extent the investee relies
Name of related party   The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from the investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs

  
Schedule of long-term investment
   June 30,
2021		   December 31,
2020		 
   (Unaudited)     
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $7,897   $7,853 
Genepharm Biotech Corporation   24,109    23,974 
BioHopeKing Corporation   895,567    890,564 
Sub total   927,573    922,391 
Equity Method Investments, net          
BioFirst Corporation   168,178    268,336 
Rgene Corporation   
-
    
-
 
Total  $1,095,751   $1,190,727 

 
Schedule of balance sheets
   June 30,
2021		   December 31,
2020		 
   (Unaudited)     
Current Assets  $1,162,565   $1,299,822 
Non-current Assets   2,605,784    2,540,041 
Current Liabilities   1,948,839    1,986,340 
Non-current Liabilities   58,745    73,197 
Stockholders’ Equity   1,760,765    1,780,326 

 

   June 30,
2021		   December 31,
2020		 
   (Unaudited)     
Current Assets  $72,532   $123,958 
Noncurrent Assets   390,079    412,342 
Current Liabilities   1,573,057    1,392,756 
Noncurrent Liabilities   19,695    38,953 
Shareholders’ Deficit   (1,130,141)   (895,409)

 
Schedule of statements of operation
   Six Months Ended
June 30,		 
   2021   2020 
   (Unaudited) 
Net sales  $13,500   $25,730 
Gross profit   3,203    3,261 
Net loss   (465,704)   (832,818)
Share of losses from investments accounted for using the equity method   (101,382)   (180,067)

 

   Six Months Ended
June 30,		 
   2021   2020 
   (Unaudited) 
Net sales  $
-
   $2,237 
Gross Profit   
-
    (331,565)
Net loss   (228,451)   (391,686)
Share of loss from investments accounted for using the equity method   
-
    
-
 

 
Schedule of equity investments
   Six Months Ended
June 30,		 
   2021   2020 
    

(Unaudited)

 
Share of equity method investee losses  $(101,382)  $(180,067)